The GREEN expertise in neurodegeneration is recognized worldwide, especially for being pioneer in the application of deep brain stimulation (DBS) in PD (Profs Benabid and Pollak’s research). This revolutionary therapy has been further applied in our center to other neurological and psychiatric diseases, such as dystonia, Tourette, epilepsy, depression, and obsessive-compulsive disorder. Moreover, PD research is focused on the non-motor features in patients with DBS, developing new criteria for the diagnosis of apathy in neurodegenerative diseases. In this context, GREEN is coordinating a national multicenter study (‘Honey-moon”) aimed at assessing the behavior of de novo PD patients. CHU is actively involved in pure french national MS Registries (OFSEP) and in several national clinical research studies such as NOMADMUS, D-Lay MS, TYSEDMUS, VIRGILE concerning MS.
GREEN’s expertise in neurodegenerative disease is also supported by technological research (advanced MR imaging and signal processing methods) and by the large number of patients (about 7000) seen every year by our center, which has stimulated the development of innovative models of multidisciplinary patient approach. In particular, the non-medical personnel (nurses, physiotherapists, psychologists, etc.) of our research teams have a central role in this patient-centered style. GREEN teams have been promoters of other innovative projects, such as the Residence AMADIEM for young AD patients and the e-service autonom@dom for seniors.
Clinical research will also benefit from the networking of GREEN with the BrainTeam network of rare diseases of the nervous system.